Literature DB >> 18525003

Extended prognostic value of urinary albumin excretion for cardiovascular events.

Auke H Brantsma1, Stephan J L Bakker, Dick de Zeeuw, Paul E de Jong, Ronald T Gansevoort.   

Abstract

Because urinary albumin excretion (UAE) is a marker of cardiovascular (CV) risk, some have proposed screening the general population; however, it is unknown how the predictive power of a single screening value changes over time. In this study, data of 8496 individuals in a community-based, prospective cohort were used to evaluate this question. For each doubling of baseline UAE, the hazard ratio (HR) for a CV event was 1.36 (95% confidence interval [CI] 1.31 to 1.42). Baseline UAE similarly predicted events occurring >5 yr after baseline, suggesting that it remains a good predictor during at least the first 5 yr after measurement. Approximately 4 yr after baseline, UAE was measured again in 6800 individuals. Once again, high UAE (>75th percentile) predicted subsequent CV events, whether defined using the baseline UAE or follow-up UAE (HR 3.39 [95% CI 2.58 to 4.45] and HR 2.50 [95% CI] 1.90 to 3.29, respectively; P = 0.3 for difference). Finally, compared with individuals with consistently low UAE, individuals who progressed from low to high UAE during follow-up had a significantly higher risk for CV events (HR 3.68; 95% CI 2.45 to 5.53). In conclusion, UAE remains a good predictor of CV events during the first 5 yr after measurement, but repeating the measurement several years later also detects progression of UAE, which is also associated with increased CV risk. Future studies are required to determine the optimal interval of repeat testing and its cost-effectiveness.

Mesh:

Year:  2008        PMID: 18525003      PMCID: PMC2518433          DOI: 10.1681/ASN.2007101065

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  20 in total

1.  Rapid progression of albumin excretion is an independent predictor of cardiovascular mortality in patients with type 2 diabetes and microalbuminuria.

Authors:  A M Spoelstra-de Man; C B Brouwer; C D Stehouwer; Y M Smulders
Journal:  Diabetes Care       Date:  2001-12       Impact factor: 19.112

2.  Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population.

Authors:  Hans L Hillege; Vaclav Fidler; Gilles F H Diercks; Wiek H van Gilst; Dick de Zeeuw; Dirk J van Veldhuisen; Rijk O B Gans; Wilbert M T Janssen; Diederick E Grobbee; Paul E de Jong
Journal:  Circulation       Date:  2002-10-01       Impact factor: 29.690

3.  Methodology of screening for albuminuria.

Authors:  R T Gansevoort; Heerspink Lambers; E C Witte
Journal:  Nephrol Dial Transplant       Date:  2007-08       Impact factor: 5.992

4.  Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals.

Authors:  H C Gerstein; J F Mann; Q Yi; B Zinman; S F Dinneen; B Hoogwerf; J P Hallé; J Young; A Rashkow; C Joyce; S Nawaz; S Yusuf
Journal:  JAMA       Date:  2001-07-25       Impact factor: 56.272

5.  Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity.

Authors:  H L Hillege; W M Janssen; A A Bak; G F Diercks; D E Grobbee; H J Crijns; W H Van Gilst; D De Zeeuw; P E De Jong
Journal:  J Intern Med       Date:  2001-06       Impact factor: 8.989

6.  Urinary albumin excretion is associated with renal functional abnormalities in a nondiabetic population.

Authors:  Sara-Joan Pinto-Sietsma; Wilbert M T Janssen; Hans L Hillege; Gerjan Navis; Dick DE Zeeuw; Paul E DE Jong
Journal:  J Am Soc Nephrol       Date:  2000-10       Impact factor: 10.121

7.  Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria.

Authors:  Peter Gaede; Lise Tarnow; Pernille Vedel; Hans-Henrik Parving; Oluf Pedersen
Journal:  Nephrol Dial Transplant       Date:  2004-08-24       Impact factor: 5.992

8.  A prospective study of microalbuminuria and incident coronary heart disease and its prognostic significance in a British population: the EPIC-Norfolk study.

Authors:  Matthew F Yuyun; Kay-Tee Khaw; Robert Luben; Ailsa Welch; Sheila Bingham; Nicholas E Day; Nicholas J Wareham
Journal:  Am J Epidemiol       Date:  2004-02-01       Impact factor: 4.897

9.  Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.

Authors:  Dick de Zeeuw; Giuseppe Remuzzi; Hans-Henrik Parving; William F Keane; Zhongxin Zhang; Shahnaz Shahinfar; Steve Snapinn; Mark E Cooper; William E Mitch; Barry M Brenner
Journal:  Circulation       Date:  2004-08-09       Impact factor: 29.690

10.  Prognostic value of urinary albumin excretion rate and other risk factors in elderly diabetic patients and non-diabetic control subjects surviving the first 5 years after assessment.

Authors:  E M Damsgaard; A Frøland; O D Jørgensen; C E Morgensen
Journal:  Diabetologia       Date:  1993-10       Impact factor: 10.122

View more
  19 in total

1.  Influence of urine creatinine on the relationship between the albumin-to-creatinine ratio and cardiovascular events.

Authors:  Caitlin E Carter; Ronald T Gansevoort; Lieneke Scheven; Hiddo J Lambers Heerspink; Michael G Shlipak; Paul E de Jong; Joachim H Ix
Journal:  Clin J Am Soc Nephrol       Date:  2012-03-01       Impact factor: 8.237

2.  The association of alcohol and smoking with CKD in a Japanese nationwide cross-sectional survey.

Authors:  Ayako Matsumoto; Yasuyuki Nagasawa; Ryohei Yamamoto; Maki Shinzawa; Yukiko Hasuike; Takahiro Kuragano; Yoshitaka Isaka; Takeshi Nakanishi; Kunitoshi Iseki; Kunihiro Yamagata; Kazuhiko Tsuruya; Hideaki Yoshida; Shouichi Fujimoto; Koichi Asahi; Toshiki Moriyama; Tsuyoshi Watanabe
Journal:  Hypertens Res       Date:  2017-03-09       Impact factor: 3.872

3.  Influence of urine creatinine concentrations on the relation of albumin-creatinine ratio with cardiovascular disease events: the Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  Caitlin E Carter; Ronit Katz; Holly Kramer; Ian H de Boer; Bryan R Kestenbaum; Carmen A Peralta; David Siscovick; Mark J Sarnak; Andrew S Levey; Lesley A S Inker; Matthew A Allison; Michael H Criqui; Michael G Shlipak; Joachim H Ix
Journal:  Am J Kidney Dis       Date:  2013-07-02       Impact factor: 8.860

4.  Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies.

Authors:  Josef Coresh; Hiddo J L Heerspink; Yingying Sang; Kunihiro Matsushita; Johan Arnlov; Brad C Astor; Corri Black; Nigel J Brunskill; Juan-Jesus Carrero; Harold I Feldman; Caroline S Fox; Lesley A Inker; Areef Ishani; Sadayoshi Ito; Simerjot Jassal; Tsuneo Konta; Kevan Polkinghorne; Solfrid Romundstad; Marit D Solbu; Nikita Stempniewicz; Benedicte Stengel; Marcello Tonelli; Mitsumasa Umesawa; Sushrut S Waikar; Chi-Pang Wen; Jack F M Wetzels; Mark Woodward; Morgan E Grams; Csaba P Kovesdy; Andrew S Levey; Ron T Gansevoort
Journal:  Lancet Diabetes Endocrinol       Date:  2019-01-08       Impact factor: 32.069

Review 5.  Aldosterone: effects on the kidney and cardiovascular system.

Authors:  Marie Briet; Ernesto L Schiffrin
Journal:  Nat Rev Nephrol       Date:  2010-03-16       Impact factor: 28.314

Review 6.  Should albuminuria be a focus of antihypertensive therapy goals?

Authors:  Radica Z Alicic; Sandeep A Saha; Robert A Short; Katherine R Tuttle
Journal:  Curr Hypertens Rep       Date:  2009-10       Impact factor: 5.369

7.  Chronic kidney disease in patients with diabetes mellitus type 2 or hypertension in general practice.

Authors:  Victor van der Meer; H Petra M Wielders; Diana C Grootendorst; Joost S de Kanter; Yvo Wj Sijpkens; Willem Jj Assendelft; Jacobijn Gussekloo; Friedo W Dekker; Ymte Groeneveld
Journal:  Br J Gen Pract       Date:  2010-12       Impact factor: 5.386

8.  Associations of urinary, glomerular, and tubular markers with the development of diabetic kidney disease in type 2 diabetes patients.

Authors:  Xu Jiang; Qian Zhang; Hua-Bin Wang; Xiao-Fan Cui; Rui Liu
Journal:  J Clin Lab Anal       Date:  2017-02-25       Impact factor: 2.352

9.  Glomerular and tubular damage markers in individuals with progressive albuminuria.

Authors:  Ferdau L Nauta; Lieneke Scheven; Esther Meijer; Wim van Oeveren; Paul E de Jong; Stephan J L Bakker; Ron T Gansevoort
Journal:  Clin J Am Soc Nephrol       Date:  2013-03-28       Impact factor: 8.237

10.  High variability of albuminuria in nondiabetic population: the Takahata Study.

Authors:  Kazuko Suzuki; Tsuneo Konta; Satoshi Takasaki; Ami Ikeda; Kazunobu Ichikawa; Hitoshi Sato; Yoko Shibata; Tetsu Watanabe; Takeo Kato; Sumio Kawata; Isao Kubota
Journal:  Clin Exp Nephrol       Date:  2009-05-20       Impact factor: 2.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.